The PrEPARE Pretoria Project: protocol for a cluster-randomized factorial-design trial to prevent HIV with PrEP among adolescent girls and young women in Tshwane, South Africa

Wendee M Wechsberg, Felicia A Browne, Jacqueline Ndirangu, Courtney Peasant Bonner, Alexandra M Minnis, Laura Nyblade, Ilene S Speizer, Brittni N Howard, Bronwyn Myers, Khatija Ahmed, Wendee M Wechsberg, Felicia A Browne, Jacqueline Ndirangu, Courtney Peasant Bonner, Alexandra M Minnis, Laura Nyblade, Ilene S Speizer, Brittni N Howard, Bronwyn Myers, Khatija Ahmed

Abstract

Background: Despite increased prevention efforts, HIV remains the leading cause of death among adolescent girls and young women in South Africa. Although research indicates important determinants of HIV acquisition at the individual and interpersonal levels, structural-level stigma and discrimination continue to be critical barriers to reaching and retaining this key population for HIV prevention and sexual and reproductive health services. Innovative and multilevel interventions are needed that can address the intersectional structural and gender issues that young women face, including stigma, alcohol and drug use, gender-based violence, and other risk factors when seeking health services. Oral pre-exposure prophylaxis (PrEP) taken daily has been found to be an effective biomedical HIV prevention tool. Testing a comprehensive gender-focused biobehavioral HIV prevention intervention that is inclusive of social ecological determinants, such as stigma and discrimination reduction in clinics, is critical for reducing HIV among adolescent girls and young women.

Methods: This project involves both a Community Collaborative Board and a Youth Advisory Board in helping to adapt the Young Women's Health CoOp intervention and the Health Policy Project (HPP) Stigma and Discrimination (S&D) reduction training curriculum to the setting and population. This study uses a two-by-two factorial design with stratified randomization of 12 clinics, each with distinct catchment areas. The Young Women's Health CoOp addresses substance use, sexual risk, violence prevention and sexual negotiation, condom demonstration, and problem solving with the following additions: knowledge of PrEP, the importance of PrEP adherence, and sexual and reproductive health. Adolescent girls and young women will be assessed with behavioral and biological measures at baseline, 3-, 6- and 9-month follow-up. The S&D reduction training is provided for all staff in the clinics randomized to this condition. Clinic staff will be surveyed at baseline, 4- and 8-month follow-up. We will recruit 900 AGYW from communities in the 12 clinic catchment areas.

Discussion: The study findings, if efficacious across the outcomes, will be incorporated into the gender-focused HIV prevention intervention toolkit and disseminated to inform multilevel prevention approaches.

Trial registration: ClinicalTrials.gov. Identifier: NCT04048551 (Recruiting). Registered: August 7, 2019 (Retrospectively registered).

Keywords: Adaptation; Alcohol and drug use; Clinic staff; Gender-based violence; HIV; Health Policy Project Stigma and Discrimination-reduction training (HPP S&D); Sexual and reproductive health (SRH); Stigma; Young Women’s Health CoOp (YWHC).

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Study Design

References

    1. UNAIDS (Joint United Nations Programme on HIV/AIDS). UNAIDS data 2019. Geneva: UNAIDS; 2019. Available from: .
    1. Simbayi LC, Zuma K, Zungu N, Moyo S, Marinda E, Jooste S, et al. South African national HIV prevalence, incidence, behaviour and communication survey, 2017. Cape Town: HSRC Press; 2019.
    1. Cunningham SD, Kerrigan DL, Jennings JM, Ellen JM. Relationships between perceived STD-related stigma, STD-related shame and STD screening among a household sample of adolescents. Perspect Sex Reprod Health. 2009;41(4):225–230.
    1. Myers B, Carney T, Wechsberg WM. “Not on the agenda”: a qualitative study of influences on health services use among poor young women who use drugs in Cape Town, South Africa. Int J Drug Policy. 2016;30:52–58.
    1. Nyblade L, Stockton M, Nyato D, Wamoyi J. Perceived, anticipated and experienced stigma: exploring manifestations and implications for young people’s sexual and reproductive health and access to care in North-Western Tanzania. Cult Health Sex. 2017;19(10):1092–1107.
    1. Wechsberg WM, Ahmed K, Ndirangu J, Browne FA, Bonner C, Speizer I, et al. Can We End HIV Among Adolescent Girls and Young Women in South Africa? Key Challenges with PrEP. Philadelphia: American Public Health Association Annual Meeting; 2019.
    1. Wechsberg W, Ndirangu J, Browne F, Peasant Bonner C, Nyblade L, Minnis A, et al. Addressing stigma and gender inequalities as antecedents to ending AIDS with adolescent women: who has the power? London: AIDSImpact; 2019.
    1. Karim QA, Meyer-Weitz A, Mboyi L, Carrara H, Mahlase G, Frohlich JA, et al. The influence of AIDS stigma and discrimination and social cohesion on HIV testing and willingness to disclose HIV in rural KwaZulu-Natal, South Africa. Global Public Health. 2008;3(4):351–365.
    1. Musheke M, Ntalasha H, Gari S, McKenzie O, Bond V, Martin-Hilber A, et al. A systematic review of qualitative findings on factors enabling and deterring uptake of HIV testing in sub-Saharan Africa. BMC Public Health. 2013;13(1):220.
    1. Sweeney SM, Vanable PA. The association of HIV-related stigma to HIV medication adherence: a systematic review and synthesis of the literature. AIDS Behav. 2016;20(1):29–50.
    1. Turan JM, Bukusi EA, Onono M, Holzemer WL, Miller S, Cohen CR. HIV/AIDS stigma and refusal of HIV testing among pregnant women in rural Kenya: results from the MAMAS study. AIDS Behav. 2011;15(6):1111–1120.
    1. Calabrese SK, Dovidio JF, Tekeste M, Taggart T, Galvao RW, Safon CB, et al. HIV pre-exposure prophylaxis stigma as a multidimensional barrier to uptake among women who attend Planned Parenthood. J Acquir Immune Defic Syndr. 2018;79(1):46–53.
    1. Amico KR, Wallace M, Bekker LG, Roux S, Atujuna M, Sebastian E, et al. Experiences with HPTN 067/ADAPT study-provided open-label PrEP among women in Cape Town: facilitators and barriers within a mutuality framework. AIDS Behav. 2017;21(5):1361–1375.
    1. Pintye J, Beima-Sofie KM, Makabong OP, Njoroge A, Trinidad SB, Heffron RA, et al. HIV-uninfected Kenyan adolescent and young women share perspectives on using pre-exposure prophylaxis during pregnancy. AIDS Patient Care STDs. 2018;32(12):538–544.
    1. Vazquez L, Moll AP, Kacin A, Ndlovu NE, Shenoi SV. Perceptions of HIV Preexposure prophylaxis among young pregnant women from rural KwaZulu-Natal, South Africa. AIDS Patient Care STDS. 2019;33(5):214–219.
    1. Velloza J, Khoza N, Scorgie F, Chitukuta M, Mutero P, Mutiti K, et al. The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study. J Int AIDS Soc. 2020;23(3):e25463.
    1. Turan JM, Elafros MA, Logie CH, Banik S, Turan B, Crockett KB, et al. Challenges and opportunities in examining and addressing intersectional stigma and health. BMC Med. 2019;17(1):7.
    1. Rao D, Elshafei A, Nguyen M, Hatzenbuehler ML, Frey S, Go VF. A systematic review of multi-level stigma interventions: state of the science and future directions. BMC Med. 2019;17(1):41.
    1. Carney T, Browne FA, Myers B, Kline TL, Howard B, Wechsberg WM. Adolescent female school dropouts who use drugs and engage in risky sex: effects of a brief pilot intervention in Cape Town, South Africa. AIDS care. 2019;31(1):77–84.
    1. Saul J, Bachman G, Allen S, Toiv NF, Cooney C, Beamon T. The DREAMS core package of interventions: a comprehensive approach to preventing HIV among adolescent girls and young women. PLoS One. 2018;13(12):e0208167.
    1. Hanscom B, Janes HE, Guarino PD, Huang Y, Brown ER, Chen YQ, et al. Brief report: preventing HIV-1 infection in women using Oral Preexposure prophylaxis: a meta-analysis of current evidence. J Acquir Immune Defic Syndr. 2016;73(5):606–608.
    1. Thomson KA, Baeten JM, Mugo NR, Bekker LG, Celum CL, Heffron R. Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women. Curr Opin HIV AIDS. 2016;11(1):18–26.
    1. CDC Statement on FDA Approval of Drug for HIV Prevention [press release]. Atlanta, Georgia: Centers for Disease Control and Prevention (CDC), July 2012. Available from: .
    1. Medicines Control Council approves fixed-dose combination of tenofovir disoproxil fumarate and emtricitabine for pre-exposure prophylaxis of HIV [press release]. 3 December 2015. Available from: .
    1. Corneli A, Namey E, Ahmed K, Agot K, Skhosana J, Odhiambo J, et al. Motivations for reducing other HIV risk-reduction practices if taking pre-exposure prophylaxis: findings from a qualitative study among women in Kenya and South Africa. AIDS Patient Care STDs. 2015;29(9):503–509.
    1. Fladseth K, Gafos M, Newell ML, McGrath N. The impact of gender norms on condom use among HIV-positive adults in KwaZulu-Natal, South Africa. PLoS One. 2015;10(4):e0122671.
    1. Teitelman AM, Jemmott JB, Bellamy SL, Icard LD, O'Leary A, Heeren GA, et al. Partner violence, power, and gender differences in south African adolescents' HIV/sexually transmitted infections risk behaviors. Health Psychol. 2016;35(7):751–760.
    1. Pettifor A, Nguyen NL, Celum C, Cowan FM, Go V, Hightow-Weidman L. Tailored combination prevention packages and PrEP for young key populations. J Int AIDS Soc. 2015;18(2 Suppl 1):19434.
    1. Bekker LG, Gill K, Wallace M. Pre-exposure prophylaxis for south African adolescents: what evidence? S Afr Med J. 2015;105(11):907–911.
    1. Corneli AL, Deese J, Wang M, Taylor D, Ahmed K, Agot K, et al. FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. J Acquir Immune Defic Syndr. 2014;66(3):324–331.
    1. van der Straten A, Brown ER, Marrazzo JM, Chirenje MZ, Liu K, Gomez K, et al. Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study. J Int AIDS Soc. 2016;19(1):20642.
    1. Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–518.
    1. Celum CL, Delany-Moretlwe S, Baeten JM, van der Straten A, Hosek S, Bukusi EA, et al. HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery. J Int AIDS Soc. 2019;22(Suppl 4):e25298.
    1. Hodges-Mameletzis I, Fonner VA, Dalal S, Mugo N, Msimanga-Radebe B, Baggaley R. Pre-exposure prophylaxis for HIV prevention in women: current status and future directions. Drugs. 2019;79(12):1263–1276.
    1. Wechsberg WM, Lam WK, Zule WA, Bobashev G. Efficacy of a woman-focused intervention to reduce HIV risk and increase self-sufficiency among African American crack abusers. Am J Public Health. 2004;94(7):1165–1173.
    1. Wechsberg WM, Bonner CP, Zule WA, van der Horst C, Ndirangu J, Browne FA, et al. Addressing the nexus of risk: biobehavioral outcomes from a cluster randomized trial of the Women’s health CoOp plus in Pretoria, South Africa. Drug Alcohol Depend. 2019;195:16–26.
    1. Wechsberg WM, Jewkes R, Novak SP, Kline T, Myers B, Browne FA, et al. A brief intervention for drug use, sexual risk behaviours and violence prevention with vulnerable women in South Africa: a randomised trial of the Women’s Health CoOp. BMJ Open. 2013;3(5):e002622.
    1. Wechsberg WM, Zule WA, Luseno WK, Kline TL, Browne FA, Novak SP, et al. Effectiveness of an adapted evidence-based woman-focused intervention for sex workers and non-sex workers: the Women's health CoOp in South Africa. J Drug Issues. 2011;41(2):233–252.
    1. Wechsberg WM, Luseno WK, Lam WK, Parry CD, Morojele NK. Substance use, sexual risk, and violence: HIV prevention intervention with sex workers in Pretoria. AIDS Behav. 2006;10(2):131.
    1. Wechsberg WM, Browne FA, Zule WA, Novak SP, Doherty IA, Kline TL, et al. Efficacy of the young Women's CoOp: an HIV risk-reduction intervention for substance-using African-American female adolescents in the south. J Child Adolesc Subst Abuse. 2017;26(3):205–218.
    1. Kidd R, Clay S, Stockton M, Nyblade L. Facilitator’s training guide for a stigma-free health facility. Washington, DC: Futures Group, Health Policy Project; 2015.
    1. Nyblade L, Addo NA, Atuahene K, Alsoufi N, Gyamera E, Jacinthe S, et al. Results from a difference-in-differences evaluation of health facility HIV and key population stigma-reduction interventions in Ghana. J Int AIDS Soc. 2020;23(4):e25483.
    1. Nyblade L, Mbuya-Brown R, Sabasaba AN, Ezekiel M, Kiwia P, Stewart C, et al. Understanding and responding to stigma and discrimination in health facilities in Tanzania. Policy brief. Washington, DC: Health Policy Plus; 2018.
    1. Nyblade L, Stewart C, Kiwia P, Manyama W, Mbuya-Brown R, Bowsky S. Towards stigma-free health facilities in Tanzania: guide for trainers. Washington, DC: Health Policy Plus; 2019.
    1. Ekstrand ML, Raj T, Heylen E, Nyblade L, Devdass D, Pereira M, et al. Reducing HIV stigma among healthcare providers in India using a partly tablet-administered intervention: the DriSti trial. AIDS Care. 2020;32(sup2):14–22.
    1. Nyblade L, Srinivasan K, Mazur A, Raj T, Patil DS, Devadass D, et al. HIV stigma reduction for health facility staff: development of a blended- learning intervention. Front Public Health. 2018;6:165.
    1. South African National AIDS Council (SANAC) Let our actions count: South Africa’s National Strategic Plan for HIV, TB and STIs (2017-2022) Pretoria: SANAC; 2017.
    1. Crespi CM. Improved designs for cluster randomized trials. Annu Rev Public Health. 2016;37(1):1–16.
    1. Mdege ND, Brabyn S, Hewitt C, Richardson R, Torgerson DJ. The 2 x 2 cluster randomized controlled factorial trial design is mainly used for efficiency and to explore intervention interactions: a systematic review. J Clin Epidemiol. 2014;67(10):1083–1092.
    1. Wechsberg WM, Ndirangu JW, Speizer IS, Zule WA, Gumula W, Peasant C, et al. An implementation science protocol of the Women’s health CoOp in healthcare settings in Cape Town, South Africa: a stepped-wedge design. BMC Womens Health. 2017;17(1):85.
    1. Wechsberg WM, Browne FA, Carney T, Myers B, Minnis A, MacDonald R, et al. The young Women's health CoOp in Cape Town, South Africa: study protocol for a cluster-randomised trial for adolescent women at risk for HIV. BMC Public Health. 2018;18(1):859.
    1. Wechsberg WM, van der Horst C, Ndirangu J, Doherty IA, Kline T, Browne FA, et al. Seek, test, treat: substance-using women in the HIV treatment cascade in South Africa. Addict Sci Clin Pract. 2017;12(1):12.
    1. Wechsberg WM, Zule WA, Ndirangu J, Kline TL, Rodman NF, Doherty IA, et al. The biobehavioral Women’s health CoOp in Pretoria, South Africa: study protocol for a cluster-randomized design. BMC Public Health. 2014;14:1074.
    1. Wechsberg WM. Revised risk behavior assessment, part I and part II. Research Triangle Park: Research Triangle Institute; 1998.
    1. Anderson PL, Liu AY, Castillo-Mancilla JR, Gardner EM, Seifert SM, McHugh C, et al. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy. Antimicrob Agents Chemother. 2018;62(1):e01710–e01717.
    1. Donner A, Klar N. Design and analysis of cluster randomization trials in Health Research. London: Arnold; 2000.
    1. Wechsberg WM, Zule WA, El-Bassel N, Doherty IA, Minnis AM, Novak SD, et al. The male factor: outcomes from a cluster randomized field experiment with a couples-based HIV prevention intervention in a south African township. Drug Alcohol Depend. 2016;161:307–315.
    1. PASS . 14.0.8 ed: NCSS LLC. 2017.
    1. STATA . 16 ed. College Station: StataCorp LLC; 2019.
    1. McGovern ME, Herbst K, Tanser F, Mutevedzi T, Canning D, Gareta D, et al. Do gifts increase consent to home-based HIV testing? A difference-in-differences study in rural KwaZulu-Natal, South Africa. Int J Epidemiol. 2016;45(6):2100–2109.
    1. Hanley JA, Negassa A, Edwardes MD, Forrester JE. Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol. 2003;157(4):364–375.
    1. Myers B, Carney T, Browne FA, Wechsberg WM. A trauma-informed substance use and sexual risk reduction intervention for young south African women: a mixed-methods feasibility study. BMJ Open. 2019;9(2):e024776.
    1. Reed SJ, Miller RL. The adolescent medicine trials network for HIVAI. The benefits of youth engagement in HIV-preventive structural change interventions. Youth Soc. 2014;46(4):529–547.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi